Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks / Nature

Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.

#healthcare #publichealth #biotech #drugdevelopment #fda #medicaldevices

Engineered protein markers read living brain gene activity in monkeys via blood

11 days / medicalxpress

Lymphovenous bypass could be potential surgical treatment for Alzheimer's disease

12 days / medicalxpress

Are tau PET scans 'lighting up' too much of the brain in Alzheimer's disease?

12 days / medicalxpress

Researchers develop cognitive tool kit enabling early Alzheimer's detection in Mandarin Chinese

13 days / medicalxpress

Eating healthy in middle age can lower risk of brain decline, study finds

13 days / medicalxpress

Women show greater tau buildup and faster cognitive decline than men in Alzheimer's

13 days / medicalxpress

Study identifies medical conditions that could predict future Alzheimer's disease

14 days / medicalxpress

Novel markers of brain blood flow and oxygenation may offer early clues to Alzheimer's risk

14 days / medicalxpress

Vanderbilt uses EHRs to flag Alzheimer’s risk factors

15 days / beckershospitalreview / Ella Jeffries

How urinary tract infections can trigger delirium and worsen dementia

15 days / medicalxpress

Blood test boosts Alzheimer's diagnosis accuracy to 94.5%, clinical study shows

16 days / medicalxpress

New Blood Test May Forecast Alzheimer’s Symptoms Years in Advance

19 days / discovermagazine

Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks

20 days / nature / Kellen K. Petersen

Saturday, February 21, 2026, 2:22 am / permalink 19513 / 13 stories in 18 days

Related Stories

Researchers report extracorporeal cross‑circulation using genetically modified pig livers / 25 days
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
FDA rejects Corcept’s cortisol modulator triggering setback / 2 months
FDA approves Rucaparib for advanced prostate cancer / 2 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 2 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 3 months
FDA Approves Ziftomenib for AML Treatment / 3 months

Related Tags

Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare

Public Health

Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #publichealth

Biotech

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

Cancer Grand Challenges awards five teams bold funding for cancer research (3 days)

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes (4 days)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.